Cargando…
HIV-I : molecular biology and pathogenesis : clinical applications /
Although it is one of the most-widely studied viruses, many mysteries still remain about HIV. Covering the latest advances and challenges associated with clinical application of new antiviral drugs and vaccines, this revised edition is a companion to Murad:HIV-1: Molecular Biology and Pathogenesis,...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Amsterdam ; Boston :
Elsevier/Academic Press,
2008.
|
| Edición: | 2nd ed. / |
| Colección: | Advances in pharmacology ;
vol. 56. |
| Temas: | |
| Acceso en línea: | Texto completo Texto completo |
MARC
| LEADER | 00000cam a2200000 a 4500 | ||
|---|---|---|---|
| 001 | SCIDIR_ocn191820152 | ||
| 003 | OCoLC | ||
| 005 | 20231117015058.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 080205s2008 ne ob 001 0 eng d | ||
| 040 | |a N$T |b eng |e pn |c N$T |d YDXCP |d OCLCQ |d IDEBK |d AU@ |d OCLCQ |d E7B |d OCLCQ |d OPELS |d OCLCQ |d OTZ |d EBLCP |d UKDOC |d DEBSZ |d OCLCQ |d MEU |d OCLCF |d UAB |d D6H |d OCLCQ |d ESU |d LEAUB |d OCLCQ |d SFB |d INARC |d OCLCQ |d OCLCO |d OCLCQ |d OCLCO | ||
| 019 | |a 271575894 |a 648331501 |a 808677258 |a 871800990 |a 904806611 |a 1004351421 |a 1030306764 |a 1127180955 |a 1175935352 | ||
| 020 | |a 9780080557229 |q (electronic bk.) | ||
| 020 | |a 0080557228 |q (electronic bk.) | ||
| 020 | |a 0123736013 |q (electronic bk.) | ||
| 020 | |a 9780123736017 |q (electronic bk.) | ||
| 020 | |a 1281144770 | ||
| 020 | |a 9781281144775 | ||
| 020 | |a 9786611144777 | ||
| 020 | |a 6611144773 | ||
| 035 | |a (OCoLC)191820152 |z (OCoLC)271575894 |z (OCoLC)648331501 |z (OCoLC)808677258 |z (OCoLC)871800990 |z (OCoLC)904806611 |z (OCoLC)1004351421 |z (OCoLC)1030306764 |z (OCoLC)1127180955 |z (OCoLC)1175935352 | ||
| 050 | 4 | |a QR201.A37 |b H58 2008eb | |
| 072 | 7 | |a MED |x 022020 |2 bisacsh | |
| 072 | 7 | |a HEA |x 039020 |2 bisacsh | |
| 082 | 0 | 4 | |a 616.979206 |2 22 |
| 245 | 0 | 0 | |a HIV-I : molecular biology and pathogenesis : |b clinical applications / |c edited by Kuan-Teh Jeang. |
| 246 | 3 | |a Clinical applications | |
| 250 | |a 2nd ed. / |b edited by J. Thomas Aug., Ferid Murad and Kuan-Teh Jeang. | ||
| 260 | |a Amsterdam ; |a Boston : |b Elsevier/Academic Press, |c 2008. | ||
| 300 | |a 1 online resource (593 pages) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Advances in pharmacology ; |v vol. 56 | |
| 500 | |a Previous edition: 2000. | ||
| 504 | |a Includes bibliographical references and index. | ||
| 588 | 0 | |a Print version record. | |
| 520 | |a Although it is one of the most-widely studied viruses, many mysteries still remain about HIV. Covering the latest advances and challenges associated with clinical application of new antiviral drugs and vaccines, this revised edition is a companion to Murad:HIV-1: Molecular Biology and Pathogenesis, 2E. Leading investigators in HIV research present a timely picture of the molecular mechanisms which guide HIV-1 expression and replication and provide the most current clinical strategies for combating this virus. * The latest developments in HIV-vaccine research * New concepts in the discovery and design of novel anti-HIV drugs. | ||
| 505 | 0 | |a Front Cover; HIV-1: Molecular Biology and Pathogenesis; Copyright Page; Contents; Contributors; Preface written by Robin A. Weiss; A. HIV Types (HIV-1 and HIV-2); B. Genotype Classification of HIV-1s; C. HIV-2: Genotype Classification and Geographic Distribution; A. Global HIV-1 Variability; B. HIV-1 Variants in Asia; C. Other HIV-1 Variants of Geographical Relevance; D. Emergence og HIV-1 Recombinants Worldwide; A. Phylogenetic Sequeuce Analysis; B. Alternative Methods (Heteroduplex Mobility Assay and Serotyping); VI. Origin of HIVs and Genesis of HIV-1 Pandemic. | |
| 505 | 8 | |a A. HIV/AIDS as a ""Zoonosis""B. Dating the Origin of Pandemic HIV-1 Strains; A. HIV-1 Subtypes and Disease Progression; B. HIV-1 Dual Infection, Superinfection, and Recombination; C. Biological Implications of Recombination; Acknowledgments; References; B. Nonnucleoside Reverse Transcriptase Inhibitors; C. Protease Inhibitors; A. Initiation of Therapy; B. Initial Regimen; C. Long-Term Management; D. Resistance; E. Drugs in Development; IV. Conclusion; References; A. Protective Role of HIV-1-Specific T-Cell Responses; B. Kinetics of HIV-1-Specific T-Cell Responses in Primary Infection. | |
| 505 | 8 | |a C. Phenotypic and Functional Profiles of HIV-1-Specific CD4 and CD8 T-Cell ResponsesD. Phenotype; E. Function; F. Specificity and Breadth of HIV-1-Specific T-Cell Responses; References; II. Background; III. Inhibition of Viral Attachment; A. gp120 Inhibitors; B. Targeting CD4; IV. Chemokine Receptors in HIV Infection; V. Targeting Coreceptor Binding; A. CXCR4 Inhibition; B. Targeting CCR5 for HIV Therapy; VI. Fusion Inhibitors; A. Targeting gp41; B. Inhibition of Membrane Fusion; VII. Resistance to Inhibitors of Viral Entry; VIII. Use Entry Inhibitors as Microbicides; References. | |
| 505 | 8 | |a B. Mechanism of HIV-1 RT DNA Polymerase ActivityA. Mechanisms of NRTI Inhibition; B. NRTI Approved for Clinical Use; C. Investigational NRTI; D. HIV-1 Resistance to NRTIs; V. Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs); A. Mechanisms of NNRTI Inhibition; B. NNRTI Approved for Clinical Use; C. Investigational NNRTI; D. HIV-1 Resistance to NNRTIs; E. Interactions Between NNRTI and NRTI Resistance Mutations; F. Use of NNRTI as Microbicides; VI. Other Inhibitors of HIV-1 RT; A. Inhibitors of HIV-1 RT RNH; B. Inhibitors of HIV-1 RT Dimerization. | |
| 505 | 8 | |a C. Inhibitors of the Initiation of Reverse TranscriptionD. RT-Directed Mutagenic Inducers; VII. Conclusion; Acknowledgments; References; A. Mechanism of Action of PIs; B. Protease Structures and Substrate-Based Inhibitors; C. Design of Symmetry-Based Inhibitors; D. Structure-Based PIs; A. Emergence of Drug Resistance to PIs; B. Primary and Secondary Mutations; C. Active site Mutants; D. Nonactive Site Mutants; E. Cleavage Site Mutants; F. Noncleavage Site Mutants; G. Insertions in Gag-Pol Polyproteins; VII. PIs with Activity Against Drug-Resistant HIV-1. | |
| 546 | |a Text in English. | ||
| 650 | 0 | |a HIV infections |x Molecular aspects. | |
| 650 | 0 | |a HIV infections |x Pathogenesis. | |
| 650 | 0 | |a HIV infections |x Treatment. | |
| 650 | 0 | |a AIDS vaccines. | |
| 650 | 2 | |a AIDS Vaccines |0 (DNLM)D016915 | |
| 650 | 6 | |a Infections �a VIH |0 (CaQQLa)201-0152700 |x Aspect mol�eculaire. |0 (CaQQLa)201-0374959 | |
| 650 | 6 | |a Infections �a VIH |0 (CaQQLa)201-0152700 |x Pathogen�ese. |0 (CaQQLa)201-0377536 | |
| 650 | 6 | |a Vaccins contre le sida. |0 (CaQQLa)201-0187992 | |
| 650 | 7 | |a MEDICAL |x AIDS & HIV. |2 bisacsh | |
| 650 | 7 | |a HEALTH & FITNESS |x Diseases |x AIDS & HIV. |2 bisacsh | |
| 650 | 7 | |a AIDS vaccines |2 fast |0 (OCoLC)fst00794025 | |
| 650 | 7 | |a HIV infections |x Pathogenesis |2 fast |0 (OCoLC)fst00949893 | |
| 650 | 7 | |a HIV infections |x Treatment |2 fast |0 (OCoLC)fst00949907 | |
| 655 | 4 | |a Electronic books. | |
| 700 | 1 | |a August, J. Thomas. | |
| 700 | 1 | |a Murad, Ferid. | |
| 700 | 1 | |a Jeang, Kuan-Teh. | |
| 776 | 0 | 8 | |i Print version: |t HIV-I : molecular biology and pathogenesis. |b 2nd ed. |d Amsterdam ; Boston : Elsevier/Academic Press, 2008 |z 9780123736017 |z 0123736013 |w (OCoLC)174129525 |
| 830 | 0 | |a Advances in pharmacology ; |v vol. 56. | |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/science/book/9780123736017 |z Texto completo |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/science/bookseries/10543589/56 |z Texto completo |